Perrigo performance snapshot after recent trading move
Perrigo (PRGO) has drawn fresh attention after a recent daily gain of about 4%. This move comes against a mixed return picture over the past year for the healthcare products group.
The recent 3.9% 1 day share price return comes after a softer patch, with the 7 day and 30 day share price returns both slightly negative, while a 39.8% 90 day gain contrasts sharply with a 26.5% decline in 1 year total shareholder return.
Compare Perrigo's sharp 90 day rebound with other potential turnaround stories by scanning our hand picked 20 high quality undiscovered gems across global markets.
Perrigo’s sharp 90 day rebound sits against multi year share price declines and ongoing net losses. Do the valuation numbers now back the recovery story, or do they still tilt toward the bear case?
Most Popular Narrative: 12% Undervalued
Perrigo’s most followed valuation story pegs fair value at $16.50 per share, which sits modestly above the recent $14.55 close and frames the current rebound as a debate about execution rather than blue sky optimism.
Strategic portfolio simplification, including the recent sale of the Dermacosmetics business, allows Perrigo to focus investment on core, higher-growth segments, bolstering gross and operating margins and accelerating deleveraging.
Ongoing operational initiatives like Project Energize and supply chain reinvention are generating $150M to $200M in savings, funding innovation and margin-accretive investments, which are expected to further improve gross margins and net earnings over time.
See why 13 investors see Perrigo as 12% undervalued.
Result: Fair Value of $16.50 (UNDERVALUED)
Still, the Perrigo story can be knocked off course if weaker category consumption lingers or if infant formula competition and quality issues continue to bite into progress.
Find out about the key risks to this Perrigo narrative.
Next Steps
Mixed signals on Perrigo so far, right? Act while the data is fresh and weigh both sides by checking the 3 key rewards and 1 important warning sign.
Looking for more Perrigo investment ideas?
If Perrigo has your attention, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match your style and risk comfort.
- Target potential value plays by scanning companies that combine earnings strength with attractive prices using our 29 high quality undervalued stocks.
- Strengthen your defense by checking out a list of solid balance sheet and fundamentals (25 results) that can help you focus on financially resilient businesses when conditions get tough.
- Dial up stability by reviewing a 31 resilient stocks with low risk scores that highlights businesses with fewer red flags and steadier profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com